BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, May 3, 2024
See today's BioWorld
Home
» Aegerion's Series A Adds $22M For Cholesterol-Lowering Work
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Aegerion's Series A Adds $22M For Cholesterol-Lowering Work
June 14, 2006
By
Jennifer Boggs
No Comments
In its first financing since it was founded in February 2005, Aegerion Pharmaceuticals Inc. raised $22.5 million in an oversubscribed Series A round to fund Phase II development of its lead dyslipidemia drug, AEGR 733. (BioWorld Today)
BioWorld